fbpx

GlaxoSmithKline

Dear Mr. Berko: My broker has recommended that I invest $20,000 and buy 500 shares of GlaxoSmithKline, a world-class drug company. The dividend is $2.48 and that yields a very attractive 5.9 percent He thinks Glaxo’s problems are over and that the stock can double in price to $80 in the coming three to five years. Please give me your thoughts on this stock. I’ve been reading your column for over 30 years. You are one of the few people I trust to give me a straight answer because you don’t have a horse in this race. — KS: Oklahoma City, OK

                Dear KS: GlaxoSmithKline (GSK-$42) has fallen from investor’s radar screens during the last few years — a consequence of several high-profile clinical failures that nearly destroyed its oncology pipeline. Its flagship asthma medication, Advair, has lost significant market share and its newer respiratory medications, like highly touted Breo Ellipta, have been painfully slow to launch.

                And GSK got caught in a 2014 bribery scandal in which a subsidiary in China was found guilty of persuading hospitals and doctors to prescribe and administer the company’s pharmaceuticals over those of its competitors. That scandal cost Glaxo nearly $500 million. Management is still bowing and scraping to improve its image and is still dealing with the aftermath that also includes bribery and improper payments in Poland, Lebanon, Romania and Jordan. Bribery is fine and acceptable in those countries (in the U.S., too) as long as one doesn’t get caught.

                Even with all that kerfuffle and brouhaha, I’d be a GSK buyer to earn a handsome 6.2 percent dividend while waiting three to five years for the shares to double in price. Apparently, management believes its problems are over and many on the street believe management will increase the dividend this year.

                In 2013, Glaxo had revenues of $42 billion, earned $3.52 a share and paid a $2.37 dividend. GSK has been bloodied by increased generic competition on some its blockbuster medications and further hammered by cheaper generics flooding the U.S. and European markets. As a result, 2014 revenues declined to $38 billion and earnings fell to $1.88 a share, but Glaxo paid a $2.66 dividend. In 2015, revenues declined again to $36 billion, earnings fell to $1.50 a share, and the dividend was reduced to $2.48.

                It’s been a tough two years for GSK as the shares foundered from $54 in 2013 to $38 last October. However, management recently bought Bristol-Myers pipeline of HIV drugs that includes some very promising late stage and early stage assets. This acquisition of promising HIV meds will strengthen one of GSK’s strongest growth platforms. GSK is already the majority owner of ViiV Healthcare, which manages the second-largest HIV business in the world. The HIV business is expected to contribute significantly to GSK’s top line comparisons. GSK also traded its oncology assets for Novartis’ vaccine business last year. This asset swap gives GSK a broad lineup of vaccine standouts that include Bexsero (immunization against invasive meningococcal meningitis) and Menveo that’s used to prevent infections caused by meningococcal bacteria. Vaccines are about 20 percent of revenues and growing. GSK’s recent launch of its high margin HIV drugs are quickly gaining market share and should add nicely to earnings in the coming years. GSK’s respiratory business is on the rebound and the company’s launch of next-generation respiratory drugs should mitigate the competition from generics. The attractive 5.9 dividend is an impressive yield especially from a quality, pale blue chip pharmaceutical company with an impressive research department and an impressive stable of effective drugs and an impressive worldwide reputation.

                T. Rowe Price, Vanguard and Fidelity combined own over 25 million shares while Institutions like Bank of New York, Royal Bank of Canada, JP Morgan, Wells Fargo, etc., own over 100 million shares. Meanwhile, Argus has a buy recommendation on the stock and so does Reuters and Bank of America. You have a wise broker and I trust his recommendation.

                Please address your financial questions to Malcolm Berko, P.O. Box 8303, Largo, FL 33775, or email him at mjberko@yahoo.com. To find out more about Malcolm Berko and read features by other Creators Syndicate writers and cartoonists, visit the Creators Syndicate website at www.creators.com.

COPYRIGHT 2016 CREATORS.COM

You May Also Like

American Heritage Schools Hosts Virtual Job Fair for Teachers

Educators around the U.S. are invited to attend.

Editor’s Letter: A Man of Nearly Unlimited Interests

Kevin Kaminski, Lifestyle Group Editor, was an honor to the profession of journalism.

Editor’s Letter: Face Time

The importance of showing up.

Kevin Kaminski (1963-2023)

The entire Lifestyle Media team—which includes South Florida Business & Wealth—is mourning the sudden loss of our extraordinary Lifestyle magazine Group Editor, Kevin Kaminski. We will honor his legacy in

Other Posts

Sommsation Celebrates “Liquid Art” During Miami Art Week

The state-of-the-art wine experience platform is the official Wine Experience sponsor of SCOPE Art Show 2023.

September Job Gains Good News for South Florida 

“September’s job report was the strongest since January of this year and showed an acceleration in late summer hiring,” says Tom Jalics, senior vice president, managing director and chief investment strategist at Fifth Third Private Bank.  

BE Connected Summit Aims to Help Small Business Owners

The group consists of powerhouse event professionals who wholeheartedly believe in the value of community. 

Editor’s Letter Expressions of Gratitude

We couldn’t do any of this without our readers and partners.

Drew Limsky

Drew Limsky

Editor-in-Chief

BIOGRAPHY

Drew Limsky joined Lifestyle Media Group in August 2020 as Editor-in-Chief of South Florida Business & Wealth. His first issue of SFBW, October 2020, heralded a reimagined structure, with new content categories and a slew of fresh visual themes. “As sort of a cross between Forbes and Robb Report, with a dash of GQ and Vogue,” Limsky says, “SFBW reflects South Florida’s increasingly sophisticated and dynamic business and cultural landscape.”

Limsky, an avid traveler, swimmer and film buff who holds a law degree and Ph.D. from New York University, likes to say, “I’m a doctor, but I can’t operate—except on your brand.” He wrote his dissertation on the nonfiction work of Joan Didion. Prior to that, Limsky received his B.A. in English, summa cum laude, from Emory University and earned his M.A. in literature at American University in connection with a Masters Scholar Award fellowship.

Limsky came to SFBW at the apex of a storied career in journalism and publishing that includes six previous lead editorial roles, including for some of the world’s best-known brands. He served as global editor-in-chief of Lexus magazine, founding editor-in-chief of custom lifestyle magazines for Cadillac and Holland America Line, and was the founding editor-in-chief of Modern Luxury Interiors South Florida. He also was the executive editor for B2B magazines for Acura and Honda Financial Services, and he served as travel editor for Conde Nast. Magazines under Limsky’s editorship have garnered more than 75 industry awards.

He has also written for many of the country’s top newspapers and magazines, including The New York Times, Washington Post, Los Angeles Times, Miami Herald, Boston Globe, USA Today, Worth, Robb Report, Afar, Time Out New York, National Geographic Traveler, Men’s Journal, Ritz-Carlton, Elite Traveler, Florida Design, Metropolis and Architectural Digest Mexico. His other clients have included Four Seasons, Acqualina Resort & Residences, Yahoo!, American Airlines, Wynn, Douglas Elliman and Corcoran. As an adjunct assistant professor, Limsky has taught journalism, film and creative writing at the City University of New York, Pace University, American University and other colleges.